MIR142 and diffuse large B-cell lymphoma: However, unlike the TERT promoter, which is commonly mutated in almost all human malignancies3, MIR142 is mutated almost exclusively (specifically) in lymphoid and myeloid malignancies, including chronic lymphocytic leukemia (CLL; 1–4%), follicular lymphoma (FL; 14–25%), diffuse large B-cell lymphoma (DLBCL; 20–27%), and acute myeloid leukemia (AML; 0.5–2% of cases) (4 and references therein).